Corbus Pharmaceuticals (NASDAQ:CRBP) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Rating) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03, MarketWatch Earnings reports. Corbus Pharmaceuticals had a negative return on equity of 55.63% and a negative net margin of 2,856.56%. NASDAQ CRBP […]

Related Keywords

Canada , ,Goldman Sachs Group Inc ,Corbus Pharmaceuticals Company Profile Get Rating ,Zacks Investment Research ,Corbus Pharmaceuticals ,Renaissance Technologies ,Corbus Pharmaceuticals Holdings Inc ,Jpmorgan Chase Co ,Earnings History For Corbus Pharmaceuticals ,Royal Bank ,Get Rating ,Marketwatch Earnings ,Investment Research ,Sigma Investments ,Goldman Sachs Group ,Sachs Group ,Pharmaceuticals Company Profile ,Pharmaceuticals Holdings ,Nasdaq Crbp ,Crbp ,Medical ,Earnings ,